Semaglutide 2.4mg for Low Responders After Bariatric Surgery

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

152

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

September 30, 2026

Conditions

ObesityObesity, MorbidWeight Gain

Interventions

OTHER

Placebo

The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.

DRUG

Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]

The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.

All Listed Sponsors

collaborator

Nederlandse Obestias Kliniek (NOK)

UNKNOWN

lead

Zuyderland Medisch Centrum

OTHER

NCT06287307 - Semaglutide 2.4mg for Low Responders After Bariatric Surgery | Biotech Hunter | Biotech Hunter